We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 31.5% gain over the past four weeks.
This rise in share price reflects growing investor optimism around CRISPR gene-editing technology. CRISPR Therapeutics remains the only company to have secured regulatory approval for a therapy based on this platform. In collaboration with Vertex Pharmaceuticals, the company markets Casgevy, which is approved to treat two blood disorders — sickle cell disease and thalassemia — across multiple regions, including the United States and Europe. CRSP is also developing a diverse pipeline, targeting immune-oncology, autoimmune and cardiovascular diseases.
This company is expected to post quarterly loss of $1.32 per share in its upcoming report, which represents a year-over-year change of -30.7%. Revenues are expected to be $7.71 million, up 1185.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For CRISPR Therapeutics, the consensus EPS estimate for the quarter has been revised 3.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CRSP going forward to see if this recent jump can turn into more strength down the road.
CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Puma Biotech (PBYI - Free Report) , another stock in the same industry, closed the last trading session 1% higher at $5.23. PBYI has returned 10% in the past month.
For Puma Biotech, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.09. This represents a change of -80% from what the company reported a year ago. Puma Biotech currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains?
CRISPR Therapeutics AG (CRSP - Free Report) shares soared 8.7% in the last trading session to close at $76.78. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 31.5% gain over the past four weeks.
This rise in share price reflects growing investor optimism around CRISPR gene-editing technology. CRISPR Therapeutics remains the only company to have secured regulatory approval for a therapy based on this platform. In collaboration with Vertex Pharmaceuticals, the company markets Casgevy, which is approved to treat two blood disorders — sickle cell disease and thalassemia — across multiple regions, including the United States and Europe. CRSP is also developing a diverse pipeline, targeting immune-oncology, autoimmune and cardiovascular diseases.
This company is expected to post quarterly loss of $1.32 per share in its upcoming report, which represents a year-over-year change of -30.7%. Revenues are expected to be $7.71 million, up 1185.5% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For CRISPR Therapeutics, the consensus EPS estimate for the quarter has been revised 3.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CRSP going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
CRISPR Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Puma Biotech (PBYI - Free Report) , another stock in the same industry, closed the last trading session 1% higher at $5.23. PBYI has returned 10% in the past month.
For Puma Biotech, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.09. This represents a change of -80% from what the company reported a year ago. Puma Biotech currently has a Zacks Rank of #3 (Hold).